|
|
IL-21 |
|
Vaxjo ID |
251 |
|
Vaccine Adjuvant Name |
IL-21 |
|
Alternative Names |
Interleukin-21 |
|
Adjuvant VO ID |
VO_0005629
|
|
Description |
A pleiotropic cytokine critical for T follicular helper (Tfh) cell development, germinal center (GC) responses, B cell help, and antibody production. In this study, IL-21 was used as an immunotherapy to boost influenza vaccine responses in aged SIV+ macaques |
|
Stage of Development |
Research |
|
Host Species for Testing |
Macaque |
|
Structure |
Recombinant IL-21 fused with an IgFc domain to enhance half-life and delivery. |
|
Preparation |
Administered subcutaneously at 50 µg/kg on days −2, 0, and +7 relative to each influenza vaccination dose. |
|
Dosage |
50 µg/kg subcutaneously Administered 3 times per vaccination cycle (days −2, 0, +7) |
|
Function |
We conclude that IL-21 enhances flu vaccine-induced Ab responses in SIV+ aged RM acting as an adjuvant modulating LN germinal center activity. Strategies to supplement IL-21 in aging could be a valuable addition in the toolbox for improving vaccine responses in an aging HIV+ population. |
|
Safety |
Well-tolerated in SIV-infected aged macaques |
| References |
Kvistad et al., 2021: Kvistad D, Pallikkuth S, Sirupangi T, Pahwa R, Kizhner A, Petrovas C, Villinger F, Pahwa S. IL-21 enhances influenza vaccine responses in aged macaques with suppressed SIV infection. JCI insight. 2021; 6(20); . [PubMed: 34491910].
|
|
